Related Experiment Video
Updated: Mar 23, 2026
Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
Hypoxic markers in non-small cell lung cancer (NSCLC) - A review
1Department of Oncology, Department of Oncology Nursing, Department of Pediatrics; Yidu Central Hospital, Weifang, Shandong, China. 1335885299@qq.com.
Abstract:
Surgery, chemotherapy and radiotherapy have been the main pillars of cancer treatment. Some of the recent improvements in survival of other cancers can be attributed to novel treatment therapies. Such therapies mostly target specific molecules involved in cancer progression and metastasis. Development and clinical introduction of targeted therapies involve identification of new and potentially important molecules in cancer progression. The next important step is to evaluate its prognostic value. Prognostication by molecular markers is also important as this may identify subgroups of patients in need for additional treatment or not, which was not possible with the traditional clinic-pathological prognosticators. Hypoxic markers have been widely explored in the recent past for their prognostic efficacy in non-small cell lung cancer. The present review article will enlighten importance of hypoxic markers with special reference to non-small cell lung carcinoma.
Insights
Novel targeted therapies improve cancer survival by targeting specific molecules. This review highlights the prognostic importance of hypoxic markers in non-small cell lung carcinoma for personalized treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
Background:
- Traditional cancer treatments include surgery, chemotherapy, and radiotherapy.
- Novel targeted therapies show promise by focusing on specific molecules driving cancer progression and metastasis.
- Molecular markers are crucial for identifying prognostic subgroups and tailoring treatments.
Purpose of the Study:
- To review the significance of hypoxic markers in cancer prognostication.
- To emphasize the role of hypoxic markers specifically in non-small cell lung carcinoma.
Main Methods:
- Literature review of studies on molecular markers and cancer prognostication.
- Focus on hypoxic markers and their clinical relevance in non-small cell lung cancer.
Main Results:
- Hypoxic markers have demonstrated prognostic efficacy in non-small cell lung cancer.
- Molecular markers offer improved patient stratification compared to traditional methods.
Conclusions:
- Hypoxic markers are vital for accurate prognostication in non-small cell lung carcinoma.
- Identifying patient subgroups through molecular markers enables personalized treatment approaches.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...